menu
    • menu
    [{"orgOrder":0,"company":"Undisclosed","sponsor":"Nika Pharmaceuticals","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Nika Pharmaceuticals, Inc. (NKPH) Purchased the Technologies for Three Drugs in Tablet Form and One Dietary Supplement","therapeuticArea":"Neurology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"April 2024","year":"2024","type":"Acquisition","leadProduct":"Vinpocetine","moa":"","url1":"","url2":"","graph1":"Neurology","graph2":"Approved","graph3":"Undisclosed","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Undisclosed \/ Nika Pharmaceuticals","highestDevelopmentStatusID":"12","companyTruncated":"Undisclosed \/ Nika Pharmaceuticals"}]

    Find Clinical Drug Pipeline Developments & Deals for 3A,16A-Apovincaminic acid ethyl ester

    Menu

    3A,16A-Apovincaminic acid ethyl ester

    ACTIVE PHARMA INGREDIENTS

    DEVELOPMENTS

    PRICE INFORMATION

    INTERMEDIATES

    FINISHED DOSAGE FORMULATIONS

    DIGITAL CONTENT

    MARKET PLACE

    REF. STANDARDS & IMPURITIES

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            Undisclosed

                            Country arrow
                            FNCE 2024
                            Not Confirmed

                            Undisclosed

                            Country arrow
                            FNCE 2024
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Vinpocetine

                            Therapeutic Area : Neurology

                            Study Phase : Approved

                            Sponsor : Nika Pharmaceuticals

                            Deal Size : Undisclosed

                            Deal Type : Acquisition

                            DEALS_DEV arrow-down

                            Nika Pharmaceuticals, Inc. (NKPH) Purchased the Technologies for Three Drugs in Tablet Form and One Dietary Su...

                            Details : The acquisition includes four technologies for production of three generic drugs in tablet form, including Vinpocetine, Menthyl Valerate, Metamizole Sodium and one dietary supplement, Tribulus Terrestris Herba Extractum Siccum.

                            Brand Name : Vinpocetine-Generic

                            Molecule Type : Small molecule

                            Upfront Cash : Undisclosed

                            April 15, 2024

                            Lead Product(s) : Vinpocetine

                            Therapeutic Area : Neurology

                            Highest Development Status : Approved

                            Sponsor : Nika Pharmaceuticals

                            Deal Size : Undisclosed

                            Deal Type : Acquisition

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            Close
                            4